WO1996031469A1 - Nouveaux composes heterocycliques - Google Patents
Nouveaux composes heterocycliques Download PDFInfo
- Publication number
- WO1996031469A1 WO1996031469A1 PCT/DK1996/000142 DK9600142W WO9631469A1 WO 1996031469 A1 WO1996031469 A1 WO 1996031469A1 DK 9600142 W DK9600142 W DK 9600142W WO 9631469 A1 WO9631469 A1 WO 9631469A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- propyl
- compound according
- ylidene
- piperidinecarboxylic acid
- compound
- Prior art date
Links
- 0 BCCCC1=C(CCC)*(C)C(CCC(C)(C)C)=C(CCCC)*1 Chemical compound BCCCC1=C(CCC)*(C)C(CCC(C)(C)C)=C(CCCC)*1 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N- substituent or salts thereof, to methods for their preparation, to comp ositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
- the invention also relates to the use of the present compounds for the treatment of insulin resistance in non-insulin- dependent diabetes mellitus (NIDDM) or aging, the present compounds knowing to interfere with neuropeptide containing C-fibres and hence inhibit the secretion and circulation of insulin antagonizing peptides li e CGRP or amylin.
- NIDDM non-insulin- dependent diabetes mellitus
- the nervous system exerts a profound effect on the inflammatory response
- Antidromic stimulation of sensory nerves results in localized vasodilation and increased vascular permeability (Janecso et al. Br. J Pharmacol 1967, 31 , 138- 151) and a similar response is observed following injection of peptides known to be present in sensory nerves
- peptides released from sensory nerve endings mediate many inflammatory responses in tissues like skin, joint, urinary tract, eye, meninges, gastro-intestinal and respiratory tracts
- inhibition of sensory nerve peptide release and/or activity may be useful in treatment of, for example arthritis, dermatitis, rhinitis asthma, cystitis, gingivitis, thrombo-phlelitis, glaucoma, gastro-intestinal diseases or migraine
- the potent effects of CGRP on skeletal muscle glycogen sy ⁇ thase activity and muscle glucose metabolism together with the notion that this peptide is released from the
- This peptide may represent an important physiological modulator of intracellular glucose trafficking in physiological conditions, such as exercise, and may also contribute to the decreased insulin action and skeletal muscle glycogen synthase in pathophysiological conditions like NIDDM or aging-associated obesity (Melnyk et al Obesity Res 3, 337-344 1995) where circulating plasma levels of CGRP are markedly increased. Hence inhibition of release and/or activity of the neuropeptide CGRP may be useful in the treatment of insulin resistance related to type 2 diabetes or aging.
- N-substituted azaheterocyclic carboxylic acids in which an oxime ether group and vinyl ether group forms part of the N-substituent respectively are claimed as inhibitors of GABA uptake
- N-substituted azacyciic carboxylic acids are claimed as GABA uptake inhibitors
- Tne present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof of formula I
- R and R 2 independently are hydrogen, halogen, trifluoromethyl, hydroxy, Ca. 6 -alkyl or C ⁇ -alkoxy;
- a together with the double bond represents a cyclic system selected from benzene, pyridine, pyrimidine, pyrazine, pyridazine, thiophene, pyrrole, furan, oxazole, isoxazole, imidazole, pyrazole or thiazole; and
- B together with the double bond represents a cyclic system selected from pyridine, pyrimidine, pyrazine, pyridazine, thiophene, pyrrole, furan, oxazole, isoxazole, imidazole, pyrazole or thiazole; and C together with the double bond represents a bicyclic system selected from naphthalene, quinoline, isoquinoline, dihydrobenzofuran, indole, benzofuran or benzothiophene; and
- R 9 independently are hydrogen or C, .6 -alkyl; and r is , 2 or 3; and m is 1 or 2; and n is 1 when m is 1 and n is 0 when m is 2; and
- R 3 and R 4 each represents hydrogen or may - when m is 2 - together represent a bond
- R 5 is -OH or Ca .6 -alkoxy; or a pharmaceutically acceptable salt thereof.
- the compounds of formula I may exist as geometric and optical isomers and all isomers and mixtures thereof are included herein. Isomers may be separated by means of standard methods such as chromatographic techniques or frac ⁇ tional crystallization of suitable salts.
- the compounds of formula I exist as the individual geometric or optical isomers.
- the compounds according to the invention may optionally exist as pharmaceuti ⁇ cally acceptable acid addition salts or - when the carboxylic acid group is not esterified - as pharmaceutically acceptable metal salts or - optionally alkylated - ammonium salts.
- salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate or similar pharmaceutically acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are hereby incorporated by reference.
- .6 -alkyr refers to a straight or branched, saturated hydrocarbon chain having 1 to 6 carbon atoms such as e g methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 4-methylpentyl, neopentyl, n-hexyl, 1 ,2-d ⁇ methylpropyl, 2,2-d ⁇ methylpropyl and 1 ,2,2-tr ⁇ methylpropyl
- C.. 6 -alkoxy refers to a straight or branched monovalent substituent comprising a C, 6 -alkyl group linked through an ether oxygen having its free valence bond from the ether oxygen and having 1 to 6 carbon atoms e g methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentoxy
- halogen means fluorine, chlorine, bromine or iodine
- the term "patient” includes any mammal which could benefit from treatment of neurogenic pain or inflammation or insulin resistance in NIDDM.
- the term particularly refers to a human patient, but is not intended to be so limited.
- the novel compounds of formula I inhibit neurogenic inflammation which involves the release of neuropeptides from peripheral and central endings of sensory C-fibres. Experimentally this can be demonstrated in animal models of formalin induced pain or paw oedema (Wheeler and Cowan, Agents Actions 1991 , 34, 264-269) in which the novel compounds of formula I exhibit a potent inhibitory effect.
- Compounds of formula I may be used to treat all painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation, i.e.: Acutely painful conditions exemplified by migraine, postoperative pain, burns, bruises, post-herpetic pain (Zoster) and pain as it is generally associated with acute inflammation; chronic, painful and/or inflammatory conditions exemplified by various types of neuropathy (diabetic, post-traumatic, toxic), neuralgia, rheumatoid arthritis, spondylitis, gout, inflammatory bowel disease, prostatitis, cancer pain, chronic headache, coughing, asthma, chronic pancreatitis, inflam ⁇ matory skin disease including psoriasis and autoimmune dermatoses, osteoporotic pain
- Acutely painful conditions exemplified by migraine, postoperative pain, burns, bruises, post-herpetic pain (Zoster) and pain
- the compounds of general formula I im- proves the glucose tolerance in diabetic ob/ob mice and that this may result from the reduced release of CGRP from peripheral nervous endings Hence the compounds of general formula I may be used in the treatment of NIDDM as well as aging-associated obesity. Experimentally this has been demonstrated by the subcutaneous administration of glucose into ob/ob mice with or without previous oral treatment with a compound of general formula I
- the compounds of formula I may be prepared by the following methods Method A:
- a compound of formula II wherein R 1 , R 2 , X, Y, A, B and r are as defined above and W is a suitable leaving group such as halogen, p-toluene sulphonate or mesylate may be reacted with an azaheterocyclic compound of formula III wherein R 3 , R 4 , R 5 , m and n are as defined above.
- This alkylation reaction may be carried out in a solvent such as acetone, dibutylether, 2-butanone, methyl ethyl ketone, ethyl acetate, tetrahydrofuran (THF) or toluene in the presence of a base e.g.
- esters have been prepared in which R 5 is alkoxy
- compounds of formula I wherein R 5 is OH may be prepared by hydrolysis of the ester group, preferably at room temperature in a mixture of an aqueous alkali metal hydroxide solution and an alcohol such as methanol or ethanol, for example, for about 0.5 to 6 h.
- a compound of formula II wherein R 1 , R 2 , X, Y, C and r are as defined above and W is a suitable leaving group such as halogen, p-toluene sulphonate or mesylate may be reacted with an azaheterocyclic compound of formula III wherein R 3 , R 4 , R 5 , m and n are as defined above.
- This alkylation reaction may be carried out in a solvent such as acetone, dibutylether, 2-butanone, methyl ethyl ketone, ethyl acetate, tetrahydrofuran (THF) or toluene in the presence of a base e.g.
- esters have been prepared in which R 5 is alkoxy
- compounds of formula I wherein R 5 is OH may be prepared by hydrolysis of the ester group, preferably at room temperature in a mixture of an aqueous alkali metal hydroxide solution and an alcohol such as methanol or ethanol, for example, for about 0.5 to 6 h
- mice About 20 g NMRI female mice were injected 20 ⁇ l 1 % formalin into the left hind paw. The animals were then placed on a heated (31°C) table, and the pain response was scored. After 1 h they were killed and bled. Left and right hind paws were removed and the weight difference between the paws was used as indication of the oedema response of the formalin injected paw.
- dosage forms suitable for oral administra ⁇ tion comprise from about 0.5 mg to about 1000 mg, preferably from about 1 mg to about 500 mg of the compounds of formula I admixed with a pharmaceutical carrier or diluent.
- the compounds of formula I may be administered in a pharmaceutically accept ⁇ able acid addition salt form or where possible as a metal or a lower alkylammo- nium salt. Such salt forms exhibit approximately the same order of activity as the free base forms.
- This invention also relates to pharmaceutical compositions comprising a com ⁇ pound of formula I or a pharmaceutically acceptable salt thereof and, usually, such compositions also contain a pharmaceutical carrier or diluent.
- the compo ⁇ sitions containing the compounds of this invention may be prepared by conven- tional techniques and appear in conventional forms, for example capsules, tablets, solutions or suspensions.
- the pharmaceutical carrier employed may be a conventional solid or liquid carrier.
- solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid.
- liquid carriers are syrup, peanut oil, olive oil and water.
- the carrier or diluent may include any time delay material known to the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
- the preparation can be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge.
- the amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g.
- the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
- the compounds of this invention are dispensed in unit dosage form comprising 50-200 mg of active ingredient in or together with a pharmaceuti ⁇ cally acceptable carrier per unit dosage.
- the dosage of the compounds according to this invention is 1-500 mg/day, e.g. about 100 mg per dose, when administered to patients, e.g. humans, as a drug.
- a typical tablet which may be prepared by conventional tabletting techniques contains
- Active compound (as free compound 100 mg or salt thereof)
- the route of administration may be any route which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, subcutaneous, intranasal, intramuscular, topical, intravenous, intraurethral, ophthalmic solution or an ointment, the oral route being preferred.
- oral or parenteral e.g. rectal, transdermal, subcutaneous, intranasal, intramuscular, topical, intravenous, intraurethral, ophthalmic solution or an ointment, the oral route being preferred.
- Triethyl phosphite (154 ml) was added to the above crude bromomethyl- thiophene and the mixture was heated at reflux temperature for 4 h and then allowed to cool to ambient temperature. The mixture was distilled in vacuo to give 123.5 g diethyl 2-bromo-3-thiophenylmethylphosphonate as an oil.
- Potassium iej_t-butoxide (56.1 g, 0.5 mol) was suspended in toluene (1 I) under an atmosphere of nitrogen and the mixture was cooled to 5 °C.
- a solution of the above phosphonate (123 g, 0.39 mol) and thiophene-3-carboxaldehyde (43.8 g, 0.39 mol) in toluene (200 ml) was added dropwise over 1 h, keeping the temperature below 10 °C. Stirring was continued at 5 °C for 0.5 h and then at ambient temperature for 16 h.
- the reaction mixture was poured into icewater (1.2 I), the phases were separated and the aqueous phase was extracted with toluene (0.5 I).
- E-(R)-1-(3-(10,11-Dihydro-5H-benzo[4,5]cyclohepta[2, 1-c]pyridin-5-ylidene)-1 - propyl)-3-piperidinecarboxylic acid ethyl ester (0.15 g, 0.38 mmol, prepared as described in example 7) was dissolved in ethanol (25 ml) and a solution of sodium hydroxide (18 mg, 0.46 mmol) in water (10 ml) was added. The reac ⁇ tion mixture was stirred for 48 h at room temperature and the solvent was removed in vacuo. Water (70 ml) was added and the mixture was washed with diethyl ether (50 ml).
- the aqueous phase was evaporated in vacuo.
- the residue was dissolved in 2-propanol (20 ml), filtered, and the solvent was evaporated in vacuo.
- the residue was suspended in acetone (10 ml) and stirred for 2 h at room temperature. The precipitate was filtered and dried in vacuo at 50°C for 24 h, to give 0.04 g (24%) of the title compound as a solid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU52707/96A AU5270796A (en) | 1995-04-07 | 1996-04-01 | N-substituted azaheterocyclic carboxylic acids and esters th ereof |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK40295 | 1995-04-07 | ||
DK40895 | 1995-04-07 | ||
DK40495 | 1995-04-07 | ||
DK0404/95 | 1995-04-07 | ||
DK0402/95 | 1995-04-07 | ||
DK0408/95 | 1995-04-07 | ||
DK1004/95 | 1995-09-11 | ||
DK100795 | 1995-09-11 | ||
DK1007/95 | 1995-09-11 | ||
DK100495 | 1995-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996031469A1 true WO1996031469A1 (fr) | 1996-10-10 |
Family
ID=27512777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1996/000142 WO1996031469A1 (fr) | 1995-04-07 | 1996-04-01 | Nouveaux composes heterocycliques |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5270796A (fr) |
IL (1) | IL117817A0 (fr) |
WO (1) | WO1996031469A1 (fr) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6281212B1 (en) | 1996-07-12 | 2001-08-28 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6288083B1 (en) | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6323206B1 (en) | 1996-07-12 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6329385B1 (en) | 1998-01-21 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6433165B1 (en) | 1998-01-21 | 2002-08-13 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6503926B2 (en) | 1998-09-04 | 2003-01-07 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6509346B2 (en) | 1998-01-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO2003045942A2 (fr) * | 1998-09-04 | 2003-06-05 | Millennium Pharmaceuticals, Inc. | Antagonistes des recepteurs de la chimiokine et methodes d'utilisation de ces antagonistes |
US6593337B1 (en) | 1999-10-19 | 2003-07-15 | Bristol-Myers Squibb Pharma Company | Tricyclic compounds useful as HIV reverse transcriptase inhibitors |
US6613905B1 (en) | 1998-01-21 | 2003-09-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6825210B2 (en) | 2001-04-19 | 2004-11-30 | Bristol-Myers Squibb Pharma Company | Tricyclic compounds useful as HIV reverse transcriptase inhibitors |
EP1688418A2 (fr) * | 2001-11-21 | 2006-08-09 | Millennium Pharmaceuticals, Inc. | Antagonistes de récepteur de chemokine et leurs procédés d'utilisation |
US7355042B2 (en) | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
US7541365B2 (en) | 2001-11-21 | 2009-06-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US7732459B2 (en) | 2002-11-13 | 2010-06-08 | Millennium Pharmaceuticals, Inc. | CCR1 antagonists and methods of use therefor |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2945031A (en) * | 1958-10-13 | 1960-07-12 | Smith Kline French Lab | Methylenedioxy substituted phenothiazines |
US3010961A (en) * | 1959-01-21 | 1961-11-28 | Geigy Chem Corp | Basically substituted derivatives of 11 hquinoxalino [2.3-b]-p-benzothiazines |
DE1166206B (de) * | 1962-04-11 | 1964-03-26 | Degussa | Verfahren zur Herstellung von 4-Azaphenthiazinderivaten |
GB993748A (en) * | 1961-07-12 | 1965-06-02 | Degussa | 4-azaphenthiazine derivatives |
GB1242096A (en) * | 1968-12-20 | 1971-08-11 | Labaz | Benzobenzofuranooxepine compounds and process for preparing the same |
-
1996
- 1996-04-01 WO PCT/DK1996/000142 patent/WO1996031469A1/fr active Application Filing
- 1996-04-01 AU AU52707/96A patent/AU5270796A/en not_active Abandoned
- 1996-04-03 IL IL11781796A patent/IL117817A0/xx unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2945031A (en) * | 1958-10-13 | 1960-07-12 | Smith Kline French Lab | Methylenedioxy substituted phenothiazines |
US3010961A (en) * | 1959-01-21 | 1961-11-28 | Geigy Chem Corp | Basically substituted derivatives of 11 hquinoxalino [2.3-b]-p-benzothiazines |
GB993748A (en) * | 1961-07-12 | 1965-06-02 | Degussa | 4-azaphenthiazine derivatives |
DE1166206B (de) * | 1962-04-11 | 1964-03-26 | Degussa | Verfahren zur Herstellung von 4-Azaphenthiazinderivaten |
GB1242096A (en) * | 1968-12-20 | 1971-08-11 | Labaz | Benzobenzofuranooxepine compounds and process for preparing the same |
Non-Patent Citations (4)
Title |
---|
COLLECT. CZECH. CHEM. COMMUN., Volume 59, 1994, KAREL SINDELAR et al., "Antihistamine Substances. Tricyclic Analogues of N-(4,4-Diphenyl-3-Butene-1-Yl)Nipecotic acid and Some Related Compounds", pages 667-675. * |
EUR. J. MED. CHEM. - CHIM. THER., Vol. 19, No. 4, 1984, SUSHIL K. DUBEY et al., "2-Methyl-1,2,3,4-Tetrahydro-10H-Pyrido (4,3-b) (1,4) Benzothiazines with Analgesic Activity", pages 371-373. * |
EUROPEAN JOURNAL OF MEDICAL CHEMISTRY, Volume 22, 1987, BRENT K. WARREN et al., "Pyridine and Reduced Pyridine Analogues of 10H-Pyrido (3,4-b) (1,4) Benzothiazines with Analgesic Activity", pages 411-415. * |
PHARMAZIE, Volume 39, 1984, P. MEISEL et al., "Synthese von 10-Substituierten 5,5-Dimethyl-5,10-Dihydrobenzo (b) (1,8) Naphthyridinen", pages 671-672. * |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6281212B1 (en) | 1996-07-12 | 2001-08-28 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6323206B1 (en) | 1996-07-12 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6509346B2 (en) | 1998-01-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6613905B1 (en) | 1998-01-21 | 2003-09-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6329385B1 (en) | 1998-01-21 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6433165B1 (en) | 1998-01-21 | 2002-08-13 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6503926B2 (en) | 1998-09-04 | 2003-01-07 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO2003045942A2 (fr) * | 1998-09-04 | 2003-06-05 | Millennium Pharmaceuticals, Inc. | Antagonistes des recepteurs de la chimiokine et methodes d'utilisation de ces antagonistes |
US6288084B1 (en) | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO2003045942A3 (fr) * | 1998-09-04 | 2003-09-12 | Millennium Pharm Inc | Antagonistes des recepteurs de la chimiokine et methodes d'utilisation de ces antagonistes |
US6288083B1 (en) | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
EA008060B1 (ru) * | 1998-09-04 | 2007-02-27 | Милленниум Фармасьютикалз, Инк. | Антагонисты хемокинного рецептора и способы их применения |
US6593337B1 (en) | 1999-10-19 | 2003-07-15 | Bristol-Myers Squibb Pharma Company | Tricyclic compounds useful as HIV reverse transcriptase inhibitors |
US6825210B2 (en) | 2001-04-19 | 2004-11-30 | Bristol-Myers Squibb Pharma Company | Tricyclic compounds useful as HIV reverse transcriptase inhibitors |
US7355042B2 (en) | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
EP1688418A3 (fr) * | 2001-11-21 | 2008-05-14 | Millennium Pharmaceuticals, Inc. | Antagonistes de récepteur de chemokine et leurs procédés d'utilisation |
SG165152A1 (en) * | 2001-11-21 | 2010-10-28 | Millennium Pharm Inc | Chemokine receptor antagonists and methods of use thereof |
US7541365B2 (en) | 2001-11-21 | 2009-06-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
KR100919346B1 (ko) * | 2001-11-21 | 2009-09-25 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 케모카인 수용체 길항제 및 이의 사용 방법 |
KR100952767B1 (ko) * | 2001-11-21 | 2010-04-14 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 케모카인 수용체 길항제 및 이의 사용 방법 |
EP1688418A2 (fr) * | 2001-11-21 | 2006-08-09 | Millennium Pharmaceuticals, Inc. | Antagonistes de récepteur de chemokine et leurs procédés d'utilisation |
JP2010229136A (ja) * | 2001-11-21 | 2010-10-14 | Millennium Pharmaceuticals Inc | ケモカイン受容体アンタゴニストおよびその使用方法 |
JP2016138122A (ja) * | 2001-11-21 | 2016-08-04 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | ケモカイン受容体アンタゴニストおよびその使用方法 |
EP2286811A1 (fr) * | 2001-11-21 | 2011-02-23 | Millennium Pharmaceuticals, Inc. | Antagonistes de récepteur de chemokine et leurs procédés d'utilisation |
US9663537B2 (en) | 2001-11-21 | 2017-05-30 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use |
US8058287B2 (en) | 2001-11-21 | 2011-11-15 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
JP4889920B2 (ja) * | 2001-11-21 | 2012-03-07 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ケモカイン受容体アンタゴニストおよびその使用方法 |
JP2013209393A (ja) * | 2001-11-21 | 2013-10-10 | Millennium Pharmaceuticals Inc | ケモカイン受容体アンタゴニストおよびその使用方法 |
JP2015083577A (ja) * | 2001-11-21 | 2015-04-30 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | ケモカイン受容体アンタゴニストおよびその使用方法 |
US7732459B2 (en) | 2002-11-13 | 2010-06-08 | Millennium Pharmaceuticals, Inc. | CCR1 antagonists and methods of use therefor |
US9334283B2 (en) | 2002-11-13 | 2016-05-10 | Millennium Pharmaceuticals, Inc. | CCR1 antagonists and methods of use thereof |
US7977350B2 (en) | 2002-11-13 | 2011-07-12 | Millennium Pharmaceuticals, Inc. | CCR1 antagonists and methods of use therefor |
Also Published As
Publication number | Publication date |
---|---|
AU5270796A (en) | 1996-10-23 |
IL117817A0 (en) | 1996-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0820451B1 (fr) | Nouveaux composes heterocycliques | |
WO1996031469A1 (fr) | Nouveaux composes heterocycliques | |
EP0820450B1 (fr) | Acides carboxyliques d'hétérocycles azotés N-substitués et leurs alkylesters | |
US6004983A (en) | N-substituted azaheterocyclic compounds | |
EP0851865B1 (fr) | Derives de 12H-Dibenzo[d,g][1,3]dioxocines | |
EP0869954B1 (fr) | Composes heterocycliques utiles dans le traitement d'une inflammation neurogenique | |
US5827856A (en) | Method of treating insulin resistance | |
US6613791B1 (en) | N-substituted azaheterocyclic carboxylic acids and their use | |
EP0820443B1 (fr) | Composes heterocycliques pour le traitement du diabete | |
US5721260A (en) | Heterocyclic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WR | Later publication of a revised version of an international search report | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |